Experienced Capital Markets Executive Addition Signals Continued Growth Acceleration NEW YORK, June 22, 2022 /PRNewswire/ Canalyst, a leading provider of financial data and analytics
Monday s breakouts: A dividend stock to watch as its share price nears oversold levels theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.
Article content
Toronto-based Enthusiast Gaming Holdings Inc. has applied to be listed on the Nasdaq exchange in the United States as it builds a “war chest” to pursue further acquisitions in the gaming and e-sports space.
The company filed its registration statement with the U.S. Securities and Exchange Commission on Tuesday to trade on the tech-heavy Nasdaq index, in a bid to broaden investor appeal. Enthusiast has been on an acquisition tear over the past few years, scooping up smaller gaming and media companies in the competitive industry.
We apologize, but this video has failed to load.
Try refreshing your browser, or
Enthusiast Gaming files for U S listing amid acquisition spree windsorstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from windsorstar.com Daily Mail and Mail on Sunday newspapers.
The Deal Would Create the Largest Enterprise in the Cannabis Industry By Revenue
Shares of Canadian Licensed-Producers (LPs) Aphria (TSX:APHA) (NYSE:APHA) (FRA: 10E) and Tilray (NASDAQ:TLRY) (FRA: 2HQ) traded higher following the news about the two companies merging. Benzinga caught up with Aphria CEO and chairman Irwin D. Simon, who will maintain those two positions in the new company, and Tilray CEO Brendan Kennedy, who will serve in the new corporation’s board of directors alongside one other person picked by Tilray, and seven others (including Simon) from Aphria.
Source: Shutterstock
Revive’s Clinical Safety Team Has Actively Monitored the Ongoing Interim Data of Patients and Found There Have Been No Safety Concerns and No Severe Adverse Events During the Interim Analysis Enrollment Period